Parkinson’s disease is known to affect 1-2 per 1,000 individuals and has been shown to impact approximately 1% of the population aged above 60 years. The disease has been estimated to incur combined direct and indirect costs of close to USD 25 billion in the US annually. Despite the availability of several types of dopamine